Avidity Biosciences Inc RNA

$72.75 -0.17 (-0.23%)

Valuation

Market cap
11,274,358,000
Revenue TTM
$10,900,000
Net income TTM
$-322,300,000
PE ratio
0.00
Forward PE
—
Profit margin
-2,956.88%
Debt to equity
0.00

Trading

Volume
4,512,920
Avg volume
2,219,330
Day's range
$72.73 – $72.98
Shares out
154,740,000
Stochastic %K
64%
Beta
0.93
Analysts
Sell
Price target
$73.83

Price

Company profile

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyo...

Show more

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Phone
619 876 0700
Website
https://atriumtherapeutics.com
Address
10578 Science Center Drive, Suite 125, San Diego, United States

Latest news